MedTrace Logo

Phase 1 Study of ELX-02 in Healthy Adults

NCT03292302 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-08-22

No results posted yet for this study

Summary

Phase 1 Single Ascending Dose Study in Normal Healthy Volunteers

Conditions

Interventions

DRUG

Placebo

Placebo comparator

DRUG

ELX-02

Synthetic aminoglycoside

Sponsors & Collaborators

  • SGS Life Sciences, a division of SGS Belgium NV

    collaborator OTHER

  • Eloxx Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-26
Primary Completion
2017-12-15
Completion
2017-12-15

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03292302 on ClinicalTrials.gov